Comparison · NCT01431209-sae
Diffuse Large B-cell Lymphoma (DLBCL) vs Peripheral T-cell Non-Hodgkin Lymphoma (PTCL): serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Diffuse Large B-cell Lymphoma (DLBCL) vs Peripheral T-cell Non-Hodgkin Lymphoma (PTCL): serious adverse events. Trial comparisons, record NCT01431209-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01431209-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.468 | 0.333 | 0.608 | wilson | |
| Risk in group 2 | 0.538 | 0.291 | 0.768 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0704 | -0.337 | 0.213 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.869 | 0.483 | 1.57 | log | |
| Odds ratio, group 1 over group 2 | 0.754 | 0.22 | 2.59 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Diffuse Large B-cell Lymphoma (DLBCL) than on Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) | 14.2 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Diffuse Large B-cell Lymphoma (DLBCL) | Patients receive ruxolitinib phosphate PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Laboratory Biomarker Analysis: Correlative studies~Ruxolitinib Phosphate: Given PO | 22 | 47 | EG000 |
| Group 2 | Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) | Patients receive ruxolitinib phosphate PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.~Laboratory Biomarker Analysis: Correlative studies~Ruxolitinib Phosphate: Given PO | 7 | 13 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
Adverse Event monitoring should be continued for at least 30 days following the last dose of study treatment. Since this treatment trial was for relapsed or refractory disease in subjects, subjects were allowed to continue study treatment as long as they received benefit and met not reason for study discontinuation. The last subject remained on treatment for 7 1/2 years.
Source ClinicalTrials.gov
Trial
- Title
- Ruxolitinib Phosphate to Treat Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma After Stem Cell Transplant
- NCT number
- NCT01431209
- Phases
- PHASE2
- Conditions
- Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
- Interventions
- Laboratory Biomarker Analysis, Ruxolitinib Phosphate
- Lead sponsor
- University of Nebraska
- Results first posted
- 2021-06-24
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01431209?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01431209-sae